Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) welcomed senior Canadian government and diplomatic leaders to the Self-Driving Lab it installed at the Korean Pharmaceutical and Biopharmaceutical Manufacturer's Association (KPBMA) in Seoul, South Korea. The visit, which took place during BIOPLUS-INTERPHEX Korea 2026 while Canada serves as Country of Honour, highlighted the facility as South Korea's first pharmaceutical Self-Driving Lab. KPBMA has now launched a multi-week training programme giving researchers from Korean biopharmaceutical organisations hands-on experience with Telescope's platform, a development investors may be watching as a signal of growing adoption.

Key Points

  • Telescope Innovations Corp. (CSE: TELI / OTCQB: TELIF / FSE: J4U) announced the high-profile visit to its KPBMA Self-Driving Lab in Seoul
  • Philip Jennings, Deputy Minister of Innovation, Science and Economic Development Canada, led the Canadian delegation alongside Embassy of Canada representatives
  • The KPBMA SDL, installed in December 2025, is South Korea's first pharmaceutical Self-Driving Lab and serves approximately 300 member companies
  • Investors may monitor uptake of the newly launched multi-week SDL researcher training programme as a commercialisation indicator

Canadian Government Delegation Visits KPBMA Self-Driving Lab in Seoul

The visit brought together Philip Jennings, Deputy Minister of Innovation, Science and Economic Development Canada (ISED), along with senior ISED representatives and officials from the Embassy of Canada to the Republic of Korea. Discussions centred on emerging innovation ecosystems in AI and automation for biopharmaceuticals and on strengthening collaboration between Canadian and Korean innovators. The announcement states the visit occurred at BIOPLUS-INTERPHEX Korea 2026, where Canada holds Country of Honour status and Telescope participates as part of the official Canadian business delegation.

KPBMA Launches Researcher Training Programme on Telescope's Platform

KPBMA, Korea's largest pharmaceutical and biotech industry association representing approximately 300 domestic and multinational member companies, is using the facility as a national training and demonstration hub. The release states that KPBMA launched a multi-week SDL training programme this week, giving researchers from Korean biopharmaceutical organisations direct experience with Telescope's automated chemistry platform. The system combines robotics, real-time analytics, and artificial intelligence to plan, execute, and analyse chemistry experiments, with the stated objective of increasing speed, reliability, throughput, and scientific insight.

Three SDL Deployments Completed in Fiscal Year 2026, Including Pfizer

According to the release, the KPBMA installation was the first of three Self-Driving Lab deployments Telescope completed in fiscal year 2026. The company's founder and CTO, Professor Jason Hein, is quoted in the announcement stating the subsequent deployments were at Pfizer in the United States and at a major global pharmaceutical company in Europe, which the release does not identify by name. The disclosure suggests Telescope has been expanding its commercial footprint across multiple geographies and customer segments within the pharmaceutical sector. The immediate share price impact was not clear from available public information.